What's Happening?
Dynamic42 and Experimental Pharmacology and Oncology (EPO), both based in Germany, have announced a strategic collaboration to integrate organ-on-chip technologies into preclinical brain cancer research. This partnership aims to address the limited availability
of preclinical models by combining Dynamic42's organ-on-chip platforms with EPO's expertise in translational oncology. The collaboration focuses on developing experimental setups that closely reflect human tumor biology, thereby generating data that translates more reliably into clinical outcomes. The initial projects target glioblastoma and the blood-brain barrier (BBB), utilizing Dynamic42's human-based BBB-on-chip model to explore therapeutic responses. This approach is expected to improve decision-making in drug development by providing more human-relevant data earlier in the process.
Why It's Important?
The collaboration between Dynamic42 and EPO is significant as it represents a shift towards more human-relevant experimental systems in cancer research. By integrating advanced in vitro systems, the partnership aims to strengthen the translational link between preclinical and clinical research, potentially reducing late-stage failure risks in drug development. This initiative supports the principles of the 3Rs (Replace, Reduce, Refine), promoting more targeted and biology-driven research strategies. The use of organ-on-chip technology could lead to more effective treatments for glioblastoma, a particularly aggressive form of brain cancer, by providing insights into the human-specific aspects of tumor biology and therapeutic responses.
What's Next?
Dynamic42 and EPO plan to present the first results of their collaboration at the American Association for Cancer Research Annual Meeting in 2026. The companies also intend to expand their collaboration to explore additional indications and extend the use of organ-on-chip technologies across different areas of drug development. This expansion could lead to further advancements in cancer research and treatment, potentially benefiting a wider range of patients.
